Cellgram-LC
Phase 3Biologic
Cellgram-LC is one of 49 biologic programs targeting Alcoholic Liver Cirrhosis. It is currently in Phase 3.
2
Indications
2
Total Trials
2
Active Trials
48
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
75 competitors in Cirrhosis
#DrugCompanyPhaseTrials
1Xifaxan
SSalix
Approved
Zocor
OOrganon and Co
Approved
Chronulac
SSolvay Pharmaceuticals
Approved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Bridion
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Bumex
VValidus Pharmaceuticals
Phase 3
Crestor
AstraZenecaPhase 2
Savaysa
Daiichi SankyoPhase 2
Eliquis
Bristol-Myers SquibbPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Cellgram-LC. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 3[1]
- Company
- PPharmicell Co., Ltd.